Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig versus placebo with best supportive care for metastatic castration-resistant prostate cancer
ISRCTN21855023Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Pasritamig with Best Supportive Care with Placebo with Best Supportive Care (2 arms). Primary endpoint: Overall survival. Started Oct 2025; status: recruiting.
02
Drugs
pasritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ISRCTN21855023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN21855023.